TD Cowen analyst Yaron Werber maintained a Buy rating on Argenx Se (ARGX – Research Report) today. The company’s shares closed yesterday at $388.69.
According to TipRanks, Werber is a 5-star analyst with an average return of 23.4% and a 61.90% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Argenx Se, and Celldex.
Argenx Se has an analyst consensus of Strong Buy, with a price target consensus of $479.29, a 23.31% upside from current levels. In a report released yesterday, Truist Financial also assigned a Buy rating to the stock with a $440.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
ARGX market cap is currently $23.1B and has a P/E ratio of -75.20.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Argenx Se (ARGX) Company Description:
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
Read More on ARGX:
